About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:3717476
Allelic
Composition
Atrtm1Bal/Atrtm2Bal
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
Genetic
Background
involves: 129S/SvEv * 129S2/SvPas * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Atrtm1Bal mutation (1 available); any Atr mutation (86 available)
Atrtm2Bal mutation (1 available); any Atr mutation (86 available)
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (4 available); any Ndor1 mutation (6 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• 1 year after tamoxifen treatment, treated mice show a 20% decrease in body weigh compared to controls (21.3 g vs 26.6 g in controls)

pigmentation
• when mice are treated with tamoxifen at 8-12 weeks of age, within 3-4 months pervasive graying of the coat is observed; no obvious phenotype is observed in controls

skeleton
• between 3 and 12 months after tamoxifen treatment, mice show significant kyphosis relative to control mice
• 1 year after tamoxifen treatment, mice show an 18% decrease in cortical bone cross-sectional area as determined by micro-CT
• 1 year after tamoxifen treatment, mice show a 46-76% reduction in trabecular bone volume as determined by micro-CT
• after tamoxifen treatment, mice begin to develop osteoporosis

endocrine/exocrine glands
• by 1-2 weeks after tamoxifen treatment, relative to controls, mice show marked suppression of thymocyte numbers which recover by 3-4 months after treatment; 6-7 months after treatment, numbers are significantly decreased again relative to controls
• hair follicles often display sebaceous gland cell hyperplasia
• mice display premature thymic involution (~1 year) after tamoxifen treatment

hematopoietic system
• by 1-2 weeks after tamoxifen treatment, relative to controls, mice show marked suppression of thymocyte numbers which recover by 3-4 months after treatment; 6-7 months after treatment, numbers are significantly decreased again relative to controls
• mice display premature thymic involution (~1 year) after tamoxifen treatment

immune system
• by 1-2 weeks after tamoxifen treatment, relative to controls, mice show marked suppression of thymocyte numbers which recover by 3-4 months after treatment; 6-7 months after treatment, numbers are significantly decreased again relative to controls
• mice display premature thymic involution (~1 year) after tamoxifen treatment
• leukocyte infiltration of the kidneys is observed in all tamoxifen-treated mice at 1 year post-treatment

liver/biliary system
• a significant increase in senescence-associated betagalactosidase-positive cells is observed in the liver 1 year after tamoxifen treatment

renal/urinary system
• leukocyte infiltration of the kidneys is observed in all tamoxifen-treated mice at 1 year post-treatment
• by 1 year after tamoxifen treatment, kidneys display atrophy
• glomerular degeneration in all kidneys of tamoxifen-treated mice at 1 year after treatment, but not in controls
• tubular degeneration in all kidneys of tamoxifen-treated mice at 1 year after treatment
• fibrotic tissue accumulates in kidneys of tamoxifen-treated mice with age

digestive/alimentary system
• 1 week after tamoxifen treatment, ~80% of villus epithelium is lost, but recovers fully by 1 months after treatment

cardiovascular system
• compared to control mice, fibrotic tissue accumulates in hearts of tamoxifen-treated mice with age

adipose tissue
• layer is reduced up to 70% in thickness 3-6 months after tamoxifen treatment

cellular
• temporary loss of proliferating cells after tamoxifen treatment is observed in intestine, skin, kidney and liver

integument
• layer is reduced up to 70% in thickness 3-6 months after tamoxifen treatment
• hair follicles often display sebaceous gland cell hyperplasia
• when mice are treated with tamoxifen at 8-12 weeks of age, within 3-4 months pervasive graying of the coat is observed; no obvious phenotype is observed in controls
• after a third round of depilation, hair regrowth does not occur or regrows predominantly gray
• when mice are treated with tamoxifen at 8-12 weeks of age, a progressive alopecia develops within 3-4 months, increasing in expressivity past 1 year of age
• single topical doses of 4-hydroxytamoxifen to skin causes alopecia and gray hair regrowth
• remaining follicles in mice >6 months display gray shafts
• after depilation in tamoxifen-treated mice, hair shaft generation is delayed and compromised in abundance and quality
• remaining hair follicles often show abnormal architecture with degeneration of dermal and epidermal structures
• significantly delayed after tamoxifen treatment
• development is delayed in anagen after tamoxifen treatment
• loss of hair follicles is observed 3-6 months after tamoxifen treatment
• following depilation in tamoxifen-treated mice, anagen phase is accompanied by widespread degenerative follicles 4 days after depilation and delay in anagen progression 8 days after depilation
• after a second round of depilation in telogen phase, hair regrowth is more sparse, with increased representation of gray hair shafts
• after a second round of depilation in telogen phase, hair regrowth is more sparse, with increased representation of gray hair shafts
• mice develop thickened epidermis 3-6 months after tamoxifen treatment


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
10/08/2019
MGI 6.14
The Jackson Laboratory